Latest / The MaineHealth Podcast / Curbside Consult - Episode 7: Adult Psychiatry with Dylan McKenney, MD
Transcript
- 0:08From the MaineHealth ACO, this is Curbside Consult, the podcast that brings
- 0:13together specialists and primary care providers for informal clinical discussions.
- 0:18I'm Heather Ward. And I'm Mike Clark. Heather and I are family physicians and
- 0:22participants in the MaineHealth ACO.
- 0:24Our featured specialty this time around is psychiatry. Woo-hoo!
- 0:28And our guest is Dr. Dylan McKinney. Dylan is the medical director for the ACO's
- 0:33Behavioral Health Care Program and is a practicing psychiatrist in private practice in Portland, Maine.
- 0:40He studied medicine at the University of Vermont and trained as a resident physician
- 0:44in psychiatry right here at our very own Maine Medical Center.
- 0:48Dylan went on to complete a fellowship in child and adolescent psychiatry at
- 0:53Maine Med, and he's certified by the American Board of Psychiatry and Neurology
- 0:58in adult, child, and adolescent psychiatry.
- 1:01Since 2023, Dylan has specialized in ketamine-assisted psychotherapy.
- 1:07Dr. Dylan McKinney, welcome to the show. Thanks so much for having me on.
- 1:12I'm really kind of curious, you know, behavioral health can be a really tough landscape to swim in.
- 1:20And wondering from your perspective and really like from my perspective as a
- 1:27primary care provider, what do you want us to know about like what is going on right now?
- 1:34Well, behavioral health is a changing landscape, but that's nothing new.
- 1:39That's the history of behavioral health. I think, you know, if we look at the
- 1:42last 200 years of behavioral health in, you know, in the U.S., in the world,
- 1:47we see repetitions of a lot of the same cycles of, you know,
- 1:52recognition of the need to provide these kinds of services to our communities.
- 1:58And then a sort of denial about that and contraction of funding and availability
- 2:04of those types of, you know, the various types of programs that are and have been.
- 2:08And right now, and honestly throughout my career, you know, we've been in that
- 2:13cycle of kind of erosion of services, especially in the public sector.
- 2:18But on the flip side, there is some really important innovation now in health
- 2:24systems that I think can provide new pathways for how we deliver mental health treatment to folks.
- 2:31Do you mind diving into some of those innovations? Well, you know,
- 2:35it's sort of ranging and there are some models for how we can deliver services differently.
- 2:41One of the big things has been that the pandemic accelerated the availability
- 2:45of telehealth services.
- 2:47And currently nationwide, there are very, I would say, very robust behavioral
- 2:52health services that are delivered virtually through various platforms and through
- 2:57various organizations.
- 2:59And that's made a huge impact on how services can be delivered,
- 3:03especially in a state like Maine, how mental health services can be delivered
- 3:08to remote populations where there are not brick-and-mortar mental health services available.
- 3:13And then, you know, kind of more on the fringe, we're starting to see the emergence
- 3:18of this machine learning and artificial intelligence impacting mental health.
- 3:23And it's both scary and exciting.
- 3:27And I've been recently learning more and more about how those products are developed
- 3:33and how important it is that they are developed specifically for mental health
- 3:39care because they can do some really bizarre and concerning things.
- 3:44The opportunity, I think, is very real for these platforms to deliver tools
- 3:50that have, you know, otherwise been very expensive historically or difficult to access.
- 3:56And so I think there's a real opportunity there to improve, you know,
- 4:00recognition of who needs mental health services and also possibly to leverage
- 4:05some of those tools to actually deliver that care. But that's a little sketchy and iffy.
- 4:10And, you know, I think we have to see how these tools can be safely developed and deployed.
- 4:15I would like to unpack some more of these cutting edge topics with you.
- 4:20But before we do, and maybe even kind of related to that is our current state
- 4:25and some of the challenges that we're facing in access to care and mental health
- 4:30care delivery. So, primary care guy, right?
- 4:32So, so much of mental health care does reside in the primary care office.
- 4:37And, you know, most of the SSRIs are probably prescribed by primary care docs.
- 4:42And so, as you have reflected upon this, kind of our current state and you,
- 4:48you know, knowing the challenges to access and do you have a picture in your
- 4:52mind of integration or of a healthcare, of a behavioral healthcare delivery
- 4:56system for the, at the population level where, where there's maybe some.
- 5:01Collaboration or integration or opportunities that we're just not tapping into.
- 5:04I mean, sometimes it feels to me like there's a big silo still between behavioral
- 5:09health care and primary care or other health care services. So what's your vision? What do you see?
- 5:15Yeah, yeah. I'm glad you asked this question. I think it's really,
- 5:20you know, I might be an outlier in this, but I see mental health services as
- 5:26really a fundamental part of primary care.
- 5:30And so in many ways, I see the right place to deliver most mental health services
- 5:35as being in the primary care office, but not necessarily by the primary care provider.
- 5:41And so I think there's a really important role for psychiatrists or,
- 5:48you know, I didn't talk about the changing workforce in psychiatry.
- 5:51There is a robust presence of psychiatric nurse practitioners that continues to grow.
- 5:55And so psychiatric providers working in the primary care setting, but also,
- 6:01you know, there are a number of changes going on that I think invite non-psychiatric
- 6:06physicians into mental health treatment and be happy to talk about those things as well.
- 6:10But, you know, since about 2017, there's been a steady increase in the number
- 6:15of non-psychiatrist physicians working in delivery of interventions like ketamine-assisted
- 6:22treatments and other types of interventions.
- 6:26So I think, you know, I would like to see that silo break down almost completely
- 6:31between mental health and primary care.
- 6:33I know, like, personally, we've had some licensed clinical social workers as
- 6:39therapists here in the office, and it's made a world of difference.
- 6:45I guess I would say as a primary care doc, it seems like having more integration
- 6:52would be something that would benefit both our patients and our providers, honestly.
- 7:00Because there is, for a provider, it feels like there's.
- 7:04Fair amount of stress at times around caring for patients with behavioral health needs.
- 7:13And there are some things that we can just do automatically.
- 7:16And then there are other things that are kind of tricky, can be a little scary.
- 7:21Yeah, yeah, absolutely. And I think, you know, in the management of most chronic
- 7:26illness, we see, you know, behavior as really a primary area of intervention, right?
- 7:35That we want people, for example, to exercise or we want people to eat differently
- 7:39or we want people to change what they're doing.
- 7:41And that's what we do in mental health. You know, we help people change their behaviors.
- 7:46To me, an exciting avenue of kind of future growth in the delivery of health
- 7:54services in general is this area of behavioral health integration in primary care services.
- 7:59I think that, you know, that all across the board, in terms of how we are reimbursed
- 8:04for our work, how we structure these things.
- 8:08Building mental health treatment in is really important. Thinking of it separately
- 8:13just creates a whole series of unnecessary problems.
- 8:17So SSRIs, SNRIs are definitely been our comfort zone and our bread and butter for prescribing.
- 8:25I don't know if I'm typical, but I've started to get more comfortable with,
- 8:30you know, for treatment-resistant depression, to start to dabble a little bit
- 8:35in like some of the atypical antipsychotics at low doses and,
- 8:38you know, more reading, more education. I feel like I could do a lot more.
- 8:42What do you think are some areas, some growth opportunities for primary care?
- 8:46Where would you say we should be reading or where are some emerging therapies
- 8:50that you think, yeah, I think this could live with primary care?
- 8:53Maybe a phone call to psychiatry, but you guys could figure this out.
- 8:56Any other emerging therapies or other treatments?
- 8:59There's been some significant growth and innovation.
- 9:04There are a lot of me-too drugs out there, especially in the atypical antipsychotic
- 9:08class that don't necessarily offer new therapeutic advantages,
- 9:12but some do and those are out there.
- 9:15Everyone sort of has their go-tos for within the accepted kind of algorithm
- 9:20of what drug to try next when the first one isn't working and so forth.
- 9:24There's not a lot of change in terms of first-line treatment,
- 9:28but there has been pretty remarkable change in some of the downstream treatment
- 9:35options available as therapeutics,
- 9:38and not all of them are drugs.
- 9:40There is this kind of newer class of pharmacotherapy for depression specifically
- 9:46and starting to make its way into other primary indications like OCD using these glutamate analogs.
- 9:53That includes, you know, some repurposing of drugs we've been using for various
- 9:57treatments for years, like amantadine and memantine that, you know,
- 10:01I frequently use now in the treatment of attentional problems in young people.
- 10:07In some cases, you know, I've seen really remarkable improvement with these
- 10:11medications in children with developmental disorders and severe behavior problems.
- 10:17A few cases of really pretty impressive response, as well as using these to
- 10:24augment treatment of severe OCD or even depression. There's a new combo drug on the market.
- 10:32Never prescribed it, but it's a combination of dextromethorphan.
- 10:36And then the development looked for a cytochrome B450 2D6 inhibitor.
- 10:44And so they landed on bupropion as the drug that they mixed in with it to make this combo pill.
- 10:51And this is available now. It has FDA approval for treatment-resistant depression.
- 10:56So that's something that's on the market.
- 11:00I've not yet prescribed dextromethorphan. There are a number of reasons why
- 11:04I'm, as a person who treats a lot of teenagers, where I'm reluctant to,
- 11:08you know, suggest it, but it does appear to, you know, to work.
- 11:14And it's the same channel, of course, that, you know, generally speaking,
- 11:17that we're trying to approach depression with ketamine.
- 11:21And so the emergence of S-ketamine as a FDA-approved treatment for treatment-resistant
- 11:26depression has ushered in this, you know, really, I would say, a,
- 11:31pretty significant wave nationwide of racemic ketamine treatment interventions.
- 11:38So that's super interesting. You've mentioned ketamine now.
- 11:41We've talked about it a couple times briefly in passing, and I'm just wondering
- 11:45if we want to jump into that a little bit.
- 11:48I am really curious, and I have had patients also approach me with regard to
- 11:55ketamine-assisted psychotherapy,
- 11:58but also some psychedelic questions, and I just don't have the answers to those.
- 12:04So can you talk a little bit about that?
- 12:07Sure, love to. It's one of my favorite topics. So after starting private practice,
- 12:12well, before I began to work with ketamine, began to learn about it in a structured
- 12:17way and did some educational activities and some peer supervision and things
- 12:21like that, learning how to use it for mental health treatment.
- 12:24But then after starting my practice. I enrolled in a one-year certification
- 12:27program with the California Institute of Integral Studies in psychedelic therapy and research.
- 12:33Got a chance to really do a deep dive into psychedelics. It's exciting after
- 12:38so many years of kind of conventional treatments to have something really.
- 12:43Really knew. It actually was around decades ago and then got completely shut down.
- 12:50So there's a lot we know about it from then. But the research that's been done
- 12:54in the past decade or so really dwarfs what had been previously done in the
- 13:00sort of first wave of psychedelic treatment.
- 13:02And of course, the only psychedelic that's legal, that's available for clinical
- 13:06use on the federal level is ketamine.
- 13:08If ketamine is in fact a psychedelic, there's a debate about that.
- 13:11It's kind of an academic point, I would view the group of new therapies as consciousness
- 13:19augmenting, you know, things that induce a non-ordinary state of consciousness,
- 13:23which we then leverage to bring people to new insights and help advance their care in that way.
- 13:31Ketamine in particular, it's clear can be thought of also as just an antidepressant
- 13:38and a really profoundly effective one.
- 13:40That glutamate pathway is the primary excitatory neurotransmitter pathway.
- 13:46And so I think John Crystal was a researcher who identified ketamine as a potential
- 13:53therapeutic for depression in the 90s and began to do the foundational research
- 13:58that led to a lot of this development.
- 14:00The way he put it is that the SSRIs and SNRIs are working kind of on like the
- 14:04dirt roads, the back roads of the brain, and ketamine is operating on the superhighway,
- 14:10you know, the primary excitatory neurotransmitter, and then also has robust
- 14:14activity at the GABA interneurons.
- 14:16So it sort of jams on the gas and cuts the brakes, and we get,
- 14:20you know, a really robust response.
- 14:22And sometimes in a ketamine treatment session, we see profound shift,
- 14:26like right in front of our.
- 14:29Almost breaks in real time. And that can be sustained for days or weeks.
- 14:36Understanding why it does when it does and why it doesn't when it doesn't is
- 14:40really where it's at in terms of research now.
- 14:44This is a very highly effective treatment for depression and like nothing I've ever seen in my career.
- 14:48And so the downside is that, as we know, ketamine has pretty profound abuse potential.
- 14:55And so we really, I think, have a big responsibility to make sure that we don't
- 15:00use it in such a way that leads to harm.
- 15:04Do you see this, the glutamate pathway, you know, as being eventually the,
- 15:12you know, first-line therapy?
- 15:14Do you see that's where we're headed? Or do you feel like it's because of the
- 15:17possible downsides, it's going to remain treatment-resistant treatment or something like that?
- 15:24Yeah, I hesitate to make too many predictions about it. But I think we're seeing
- 15:31sort of steady improvement in the evidence about the use of this intervention.
- 15:36I say this intervention, but when we talk about ketamine treatment,
- 15:40we might be talking about any number of things in an array of kind of delivery methods.
- 15:47So I think the scariest one is you make an appointment online and you pay X
- 15:54number of dollars and then someone ships a whole bunch of ketamine to your house
- 15:58and then you use that maybe with some supervision or not versus the way that
- 16:05I have learned to practice it,
- 16:06which is a very highly controlled in-office setting where I'm delivering.
- 16:10In my case, I deliver intramuscular injections of ketamine in a very specific
- 16:16dosing strategy to achieve the treatment goals that we're working on.
- 16:21And that is somewhat comparable to the way that the S-ketamine is delivered,
- 16:28which I don't currently work with.
- 16:30S-ketamine is, I think, the availability of it is probably improving in communities.
- 16:37So that too is, you know, meant.
- 16:41Be controlled in such a way that it's not redirectable, the supply is not redirectable,
- 16:46and that people don't have the option to use it in ways other than pointedly for their treatment.
- 16:56So obviously, depression plays a huge role in the dollars that we spend on health care.
- 17:07And I think also secondarily, if we're depressed, we're not taking care of ourselves,
- 17:12and that leads to a whole myriad of other problems.
- 17:16What role do you think that, I don't know if we want to talk about ketamine
- 17:20specifically or treatment of depression in general, plays in value-based care?
- 17:26It's a great question. It's a big one. And I think treating depression effectively
- 17:32and quickly is in the best interest of all.
- 17:36You know, that depression takes a huge toll on one's, you know,
- 17:39personally on one's productivity, one's accuracy in job performance, for example.
- 17:45You know, the novel therapeutics, I think, come in in a couple of different ways.
- 17:48One, they can, in many cases, treat people who are doing so badly that they
- 17:54might need hospital care or other intensive interventions that would be much
- 17:57more costly and disrupt personal routines, etc.
- 18:01Ketamine, as an example, has been compared head-to-head with ECT,
- 18:05and a landmark study found in a specific ketamine intervention,
- 18:10a 40-minute half a milligram per kilogram infusion with a particular frequency
- 18:15and duration to be, quote, not inferior to ECT,
- 18:19which is a really remarkable finding
- 18:21when you consider how invasive ECT is compared to ketamine treatment.
- 18:26Important questions remain about how to deliver it, you know, etc.
- 18:30But these are some exciting changes that, you know, that I think from a value-based
- 18:34care perspective, lend a lot to improving outcomes and reducing cost.
- 18:39So Dylan, as we wrap up, looking ahead into the future,
- 18:45you know, get your crystal ball, looking ahead five years, 10 years,
- 18:47what do you think will change the most in how we approach diagnosis and treatment
- 18:53of mental health conditions in the population that we care for?
- 18:56I mean, it's incredibly hard to predict, but I think that one possibility that's
- 19:02actually very real is that we have.
- 19:05You know, we develop these machine learning tools which can help us to deeply
- 19:11and profoundly understand the mental health problems in patient population and
- 19:17who needs the help and how to deliver it.
- 19:20That the ability to target what we do, the interventions that we have,
- 19:24and have those land in the right place at the right time could very significantly improve.
- 19:30It's interesting to point out, too, that some of these AI platforms,
- 19:34the response from people who use them about the degree to which they feel understood
- 19:40and perceive themselves to be having very, like,
- 19:43compassionate and empathic interaction, remarkable.
- 19:47I'm not ignoring the fact that there's some really scary possibilities here,
- 19:51but there's also this incredibly exciting
- 19:54possibility that I could see about the role of these AI platforms in making
- 20:00accurate diagnosis and getting really robust information and being able to predict
- 20:06things like who is at risk of suicide and in ways that we have not previously been able to do.
- 20:12Well, this has been fantastic, really exciting, and I think we're going to have to bring you back,
- 20:19if not in the next few months, in the next year or so, and find out where we
- 20:24are with AI and all of these changes that you're talking about.
- 20:29Thank you so much for joining us today. My pleasure. This has been fun. Thanks for having me.
- 20:36Thanks for listening to Curbside Consult. To continue the conversation,
- 20:40please visit the MaineHealth ACO's LinkedIn page at.
- 20:50We welcome your reactions, thoughts, and suggestions for what specialties to
- 20:55cover in the months to come. See you next time. See you next time.
- 21:06Amen.